As proof of the principle that the eIF2α pathway can be targeted for the treatment of leishmaniasis, we tested a library of N′N-diarylurea and cHAU compounds against Leishmaia parasites and, using a discovery funnel, chose I-17 for in-depth studies. Here, EIF2A is linked to leishmaniasis.